Pain free efficacy of sumatriptan in the early treatment of migraine.
Can J Neurol Sci
; 33(1): 73-9, 2006 Feb.
Article
en En
| MEDLINE
| ID: mdl-16583726
ABSTRACT
BACKGROUND:
There is evidence that headache response rates may be higher if triptans are used early when a migraine attack is still mild, as compared to when it is treated after pain has reached moderate or severe intensity.METHODS:
In this randomized, double blind, placebo controlled, parallel group clinical trial, 361 patients took either placebo, sumatriptan 50 mg, or sumatriptan 100 mg in a single attack study. The primary outcome measure was pain-free status at two hours.RESULTS:
In the intention to treat group, two hour pain free rates were 16%, 40%, and 50% in the placebo group, sumatriptan 50 mg group, and the sumatriptan 100 mg group respectively (p < 0.001, active treatment groups vs. placebo).CONCLUSIONS:
Both sumatriptan 50 mg and 100 mg were significantly superior to placebo for the pain-free end point at two hours. The pain-free response rates in this trial where sumatriptan was taken while the headache was still mild were generally higher than in older clinical trials where headache was treated after reaching a moderate or severe intensity.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Dolor
/
Agonistas de Receptores de Serotonina
/
Sumatriptán
/
Trastornos Migrañosos
Tipo de estudio:
Clinical_trials
/
Etiology_studies
Límite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Can J Neurol Sci
Año:
2006
Tipo del documento:
Article
País de afiliación:
Canadá